Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Flanagan

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cancers|February 11, 2023
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer MassesNirmala Chandralega Kampan, Apriliana Ellya Ratna Kartikasari, Cyril Deceneux, et al.
Oncogene|September 26, 2003
Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilizationPuneeth Iyengar, Terry P Combs, Shalin J Shah, et al.
Trials|October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
British Journal of Haematology|April 21, 2015
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trialSteve Schey, Sarah R Brown, Avie-Lee Tillotson, et al.
Histopathology|October 22, 2013
Investigation of molecular alterations of AKT-3 in triple-negative breast cancerGillian O'Hurley, Etáin Daly, Anthony O'Grady, et al.
BMC Cancer|November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
The FEBS Journal|June 23, 2015
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patientsFiona Lanigan, Gerard L Brien, Yue Fan, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancers|February 11, 2023
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer MassesNirmala Chandralega Kampan, Apriliana Ellya Ratna Kartikasari, Cyril Deceneux, et al.
Oncogene|September 26, 2003
Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilizationPuneeth Iyengar, Terry P Combs, Shalin J Shah, et al.
Trials|October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
British Journal of Haematology|April 21, 2015
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trialSteve Schey, Sarah R Brown, Avie-Lee Tillotson, et al.
Histopathology|October 22, 2013
Investigation of molecular alterations of AKT-3 in triple-negative breast cancerGillian O'Hurley, Etáin Daly, Anthony O'Grady, et al.
BMC Cancer|November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
The FEBS Journal|June 23, 2015
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patientsFiona Lanigan, Gerard L Brien, Yue Fan, et al.
Pageof 3